– SWITZERLAND, Allschwil – Engimmune Therapeutics AG, a Swiss biotech company developing novel T-cell receptor (TCR)-based therapeutics, today announced the appointment of Dr. Annalisa D’Andrea to its Board as a Non-Executive Director effective on 1st June 2023.
About Dr. Annalisa D’Andrea
Dr. Annalisa D’Andrea has over 25 years of experience in the life-science industry including immunology research, drug discovery and development, and strategic leadership in biotechnology and pharmaceutical companies. She is a Venture Partner at Longwood Fund and is the former President and CSO of ImmuneID. Before ImmuneID she was CSO of Kiniksa Pharmaceuticals. She was previously VP and Global Head of Discovery for Immunology and Inflammation at Roche, where she oversaw the discovery pipeline of drug candidates from inception to the clinic. Before Roche, Dr. D’Andrea held several executive positions at SRI International, including Executive Director and Section Head of Discovery Biology, where she was responsible for advancing assets through discovery and into development. Earlier in her career, she worked at Chiron Vaccines in Siena, Italy, an American multinational biotechnology firm later acquired by Novartis and most recently by GSK.
Dr. Annalisa D’Andrea was educated in Italy and the United States and has authored more than 46 publications and is the co-inventor of several patents. She received her Bachelor of Sciences, summa cum laude from the University of Siena in Italy, and her doctoral degree from the University of Florence while training at the Wistar Institute at the University of Pennsylvania. She completed her postdoctoral studies at the DNAX Research Institute in Palo Alto, California.
About Engimmune Therapeutics
Engimmune Therapeutics is developing breakthrough TCR-based therapies, which are broadly divided into TCR-redirected T cell therapies and soluble TCR biologics and leverage TCR recognition of antigens to promote targeted cytotoxicity for the treatment of oncology and immune-mediated diseases. Engimmune’s next-generation TCR technology platform is advancing into the next stage of growth and development as it prepares for future clinical development and commercialization.
Engimmune Therapeutics is a technology platform and product-based company using cutting-edge technologies to engineer highly potent and specific T-cell receptor therapies. By applying proprietary platform technologies combining genome editing, functional high-throughput screening, deep sequencing, and machine learning, Engimmune addresses key efficacy and safety challenges that currently limit the full potential of TCR-T cell and soluble TCR therapeutics. The Company was founded in 2021.
Source: https://www.engimmune.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.